BLOGS & ARTICLES

BRSF_Brain_Binary_NewsThumbnail

Brain Scientific Announces Private Placement of $5.6 Million of Senior Secured Convertible Debentures and Warrants, Converts Approximately $12.9 Million of Existing Debt into Equity

June 15, 2022

Brain Scientific (OTCQB: BRSF) (the “Company”), a medical technology company with multiple patents and FDA-cleared products, today announces that it has entered into definitive agreements with certain institutional and accredited investors for the sale of senior secured convertible debentures and warrants to purchase shares of the Company’s common stock, resulting in total gross proceeds of approximately $5.1 million before deducting the placement agent’s fees and other offering expenses.

Read More

Brain Scientific Announces CE Mark Approval for NeuroCap™ Device

August 24, 2022

The CE mark confirms that Brain Scientific meets all European Medical Device Directive requirements to begin commercializing its innovative neurological devices across the European Continent and other CE mark geographies.

Read More

Daniel Cloutier, a Veteran Sales Executive, Joins Brain Scientific as Chief Revenue Officer

November 1, 2022

Company Continues to Build Momentum as It Launches Its Disruptive Technologies in the Marketplace

Read More

Brain Scientific Announces Release of Improved NeuroCap(TM) and New US Distribution Deal with D&D Medical

November 15, 2022

Company Continues to Build Momentum as It Launches Its Disruptive Technologies in the Marketplace

Read More

Brain Scientific Inks Deal with Fulcrum to Go After At-Home Diagnostic Space, Hires VP of Marketing and Communications

December 1, 2022

Fulcrum leverages their experience and network of at-home diagnostic service providers, and Kevin Winterfield joins as vice president of marketing and communications to accelerate brand awareness and sales

Read More

Your questions are important to us.

Have a question? Contact Brain Scientific and a member of our team will reach back out to you.